Ten-Year Relative Survival for Epithelial Ovarian Cancer
Top Cited Papers
- 31 August 2012
- journal article
- conference paper
- Published by Ovid Technologies (Wolters Kluwer Health) in Obstetrics and Gynecology
- Vol. 120 (3), 612-618
- https://doi.org/10.1097/AOG.0b013e318264f794
Abstract
OBJECTIVE: Most patients with epithelial ovarian cancer who are alive at 5 years have active disease. Thus, 10-year survival rather than 5-year survival may be a more appropriate endpoint. Relative survival adjusts for the general survival of the United States population for that race, sex, age, and date at which the diagnosis was coded. Our objective was to estimate relative survival in epithelial ovarian cancer over the course of 10 years. METHODS: Using the Surveillance, Epidemiology and End Results 1995-2007 database, epithelial ovarian cancer cases were identified. Using the actuarial life table method, relative survival over the course of 10 years was calculated, stratified by stage, classification of residence, surgery as the first course of treatment, race, and age. RESULTS: There were 40,692 patients who met inclusion criteria. The overall relative survival was 65%, 44%, and 36% at 2, 5, and 10 years, respectively. The slope of decline in relative survival was reduced for years 5-10 as compared with years 1-5 after diagnosis. Relative survival at 5 years was 89%, 70%, 36%, and 17%, and at 10 years relative survival was 84%, 59%, 23%, and 8% for stages I, II III, and IV, respectively. At all stages, patients with nonsurgical primary treatment and those with advanced age had reduced relative survival. CONCLUSIONS: The 10-year relative survival for stage III is higher than expected. This information provides the physician and the patient with more accurate prognostic information. (Obstet Gynecol 2012; 120: 612-8) DOI: http://10.1097/AOG.0b013e318264f794 LEVEL OF EVIDENCE: IIIKeywords
This publication has 24 references indexed in Scilit:
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Optimal Management of Recurrent Ovarian CancerInternational Journal of Gynecologic Cancer, 2009
- Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trialsCancer, 2009
- A Population-Based 5-Year Cohort Study Including All Cases of Epithelial Ovarian Cancer in Western Sweden: 10-Year Survival and Prognostic FactorsInternational Journal of Gynecologic Cancer, 2009
- Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancerAmerican Journal of Obstetrics and Gynecology, 2007
- Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJournal of Clinical Oncology, 2006
- Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR TrialAnnals of Surgical Oncology, 2006
- Treatment goals in ovarian cancerInternational Journal of Gynecologic Cancer, 2005
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- On the estimation of survivalSeminars in Surgical Oncology, 1994